KKR will acquire Integer Holdings in an all-cash transaction valuing the medical device manufacturer at $5.7 billion, including debt assumption. The deal price represents a 34% premium to Integer's thirty-day volume-weighted average and closes the largest private equity take-private in medical technology since Bain Capital's $4.2 billion acquisition of Olympus Scientific Solutions in February 2023.
Integer manufactures components for cardiac rhythm management devices, neuromodulation systems, and portable medical products. The company supplies original equipment to every major pacemaker and defibrillator manufacturer globally. Revenue for the trailing twelve months ending June 2026 reached $1.68 billion, with EBITDA margins expanding to 21.3% from 18.7% two years prior. KKR is acquiring a business with $840 million in net debt and annual free cash flow approaching $190 million.
The transaction reflects three converging trends allocators have tracked since mid-2025. First, private equity is returning to healthcare infrastructure plays after a two-year drought in mega-deals, with dry powder in healthcare-focused funds exceeding $180 billion as of Q2 2026. Second, Integer's customer concentration—four clients represent 62% of revenue—creates precisely the kind of embedded switching cost KKR has monetized in prior medtech holdings. Third, the regulatory moat around cardiac device components has widened materially since FDA enforcement actions in 2024 forced three offshore competitors to exit the U.S. market entirely. Integer now holds one of seven active FDA establishment registrations for Class III cardiac component manufacturing in North America.
KKR's healthcare vertical has deployed $14.3 billion across six platform acquisitions since January 2024, focusing exclusively on regulated manufacturing with recurring revenue models. The firm's 2021 take-private of Cotiviti, a healthcare analytics provider, returned 2.8x to LPs through a combination of operational improvements and multiple expansion before exiting to a strategic buyer in late 2025. Integer fits the same profile: predictable cash generation, consolidated customer base, and margin expansion opportunity through automation and offshore capacity rationalization.
Operators should monitor three specific catalysts. Integer's largest customer, Medtronic, is expected to announce its next-generation pacemaker platform in Q4 2026, which would lock in component specifications for a seven-to-nine-year product cycle. KKR will likely move to refinance Integer's $840 million debt stack within ninety days of close, targeting a blended cost below 5.2% versus the current 6.8%. The firm has signaled interest in bolt-on acquisitions within neuromodulation components, where three privately held competitors with combined revenue near $400 million are currently running sale processes.
The deal is expected to close in Q1 2027, subject to shareholder approval and customary regulatory clearances. Integer's board unanimously recommended acceptance, with management rolling forward an undisclosed equity stake. KKR is funding the transaction through its Americas XII fund, which closed at $19.4 billion in March 2025 and has deployed $11.2 billion to date across fourteen platform investments.